PDCD1 and neoplasm: Moreover, plasmacytoid DCs promote tumor plasma cell growth, survival, and drug resistance (66) and express high surface levels of programmed death-ligand 1 (PD-L1) conferring T cell and NK cell immune suppression by engaging ICP via PD1-PD-L1 signaling axis (67, 68).